Litcius/Paper detail

Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson’s disease

Hideaki Matsui, Shinji Ito, H. Matsui, Junko Itô, Ramil Gabdulkhaev, Mika Hirose, Tomoyuki Yamanaka, Akihide Koyama, Taisuke Kato, Maiko Tanaka, Norihito Uemura, Noriko Matsui, Sachiko Hirokawa, Maki Yoshihama, Aki Shimozawa, Shinichiro Kubo, Kenji Iwasaki, Masato Hasegawa, Ryōsuke Takahashi, Keisuke Hirai, Akiyoshi Kakita, Osamu Onodera

2023Proceedings of the National Academy of Sciences24 citationsDOIOpen Access PDF

Abstract

α-Synuclein accumulates in Lewy bodies, and this accumulation is a pathological hallmark of Parkinson's disease (PD). Previous studies have indicated a causal role of α-synuclein in the pathogenesis of PD. However, the molecular and cellular mechanisms of α-synuclein toxicity remain elusive. Here, we describe a novel phosphorylation site of α-synuclein at T64 and the detailed characteristics of this post-translational modification. T64 phosphorylation was enhanced in both PD models and human PD brains. T64D phosphomimetic mutation led to distinct oligomer formation, and the structure of the oligomer was similar to that of α-synuclein oligomer with A53T mutation. Such phosphomimetic mutation induced mitochondrial dysfunction, lysosomal disorder, and cell death in cells and neurodegeneration in vivo, indicating a pathogenic role of α-synuclein phosphorylation at T64 in PD.

Topics & Concepts

PhosphorylationNeurodegenerationAlpha-synucleinOligomerParkinson's diseaseMutationCell biologyBiologySynucleinPathogenesisSynucleinopathiesProgrammed cell deathChemistryBiochemistryDiseaseMedicinePathologyImmunologyApoptosisGeneOrganic chemistryParkinson's Disease Mechanisms and TreatmentsLysosomal Storage Disorders ResearchNeurological disorders and treatments
Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson’s disease | Litcius